Conference Proceedings
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
CS Tam, T Siddiqi, JN Allan, TJ Kipps, IW Flinn, BJ Kuss, S Opat, PM Barr, A Tedeschi, R Jacobs, XC Badoux, P Ghia, J Sukbuntherng, AH Salem, K Russell, K Eckert, C Zhou, J Ninomoto, DF James, WG Wierda
Blood | AMER SOC HEMATOLOGY | Published : 2019
Abstract
DISCLOSURES: Tam: Novartis: Honoraria; Pharmacyclics LLC, an AbbVie company: Honoraria; AbbVie: Honoraria, Research Funding; BeiGene: Honoraria; Janssen: Honoraria, Research Funding; Roche: Honoraria. Siddiqi:Astra Zeneca: Consultancy, Other: Travel, Accommodations, Expenses, Research Funding, Speakers Bureau; Kite: Research Funding; TG Therapeutics: Research Funding; Celgene: Research Funding; BeiGene: Research Funding; Seattle Genetics: Speakers Bureau; Janssen: Speakers Bureau; Pharmacyclics LLC, an AbbVie company: Consultancy, Research Funding, Speakers Bureau; Juno: Consultancy, Research Funding. Allan:Bayer: Consultancy; Verastem Oncology, Inc.: Consultancy, Membership on an entity's B..
View full abstract